海王英特龙2024年报

ANNUAL REPORT年 報2024 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGEOF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM GEM has been positioned as a market designed to accommodatesmall and mid-sized companies to which a higher investment riskmay be attached than other companies listed on the Stock Exchange.Prospective investors should be aware of the potential risks ofinvesting in such companies and should make the decision to investonly after due and careful consideration. GEM Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may bemore susceptible to high market volatility than securities traded onthe Main Board and no assurance is given that there will be a liquidmarket in the securities traded on GEM. GEMGEMGEM Hong Kong Exchanges and Clearing Limited and the Stock Exchange take noresponsibility for the contents of this report, make no representation as to itsaccuracy or completeness and expressly disclaim any liability whatsoever forany loss howsoever arising from, or in reliance upon, the whole or any partof the contents of this report. G E MGEM This report, for which the directors (the “Directors”) of Shenzhen NeptunusInterlong Bio-technique Company Limited (the “Company”) collectively andindividually accept full responsibility, includes particulars given in compliancewith the Rules Governing the Listing of Securities on GEM of the StockExchange (the “GEM Listing Rules”) for the purpose of giving informationwith regard to the Company. The Directors, having made all reasonableenquiries, confirm that to the best of their knowledge and belief theinformation contained in this report is accurate and complete in all materialrespects and not misleading or deceptive, and there are no other mattersthe omission of which would make any statement herein or this reportmisleading. Corporate Information公司資料 Directors Executive DirectorsMr. Zhang Feng(Chairman)Mr. Huang Jian BoMr. Zhang Xiao Guang Non-Executive Directors Mr. Zhang Yi FeiMs. Yu LinMr. Jin Rui Independent Non-Executive Directors Mr. Yick Wing Fat, SimonMr. Poon Ka YeungMr. Zhang Jian Zhou Supervisors Mr. Xiong Chu XiongMr. Jin GeMs. Cao Yang Members of Remuneration Committee Mr. Poon Ka Yeung(Chairman of the Remuneration Committee)Mr. Zhang FengMr. Yick Wing Fat, Simon Members of Audit Committee Mr. Yick Wing Fat, Simon(Chairman of the Audit Committee)Mr. Poon Ka YeungMs. Yu Lin Members of Nomination Committee Mr. Zhang Feng(Chairman of the Nomination Committee)Mr. Yick Wing Fat, SimonMr. Poon Ka YeungMr. Zhang Jian Zhou Company Secretaries Mr. Huang Jian BoMs. Fung Wai Sum Corporate Information公司資料 Compliance Officer Mr. Zhang Feng Authorised Representatives Mr. Zhang FengMr. Huang Jian Bo AuditorsGrant Thornton Hong Kong Limited 97943 Legal AdviserStephenson Harwood43/F, One Taikoo Place, 979 King’s Road, Quarry Bay, Hong Kong Principal Bank China Construction Bank Shenzhen CBD Sub-branch H1617 H Share Registrar and Transfer Office Tricor Investor Services Limited17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong Registered Office 11702 Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road,Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, ThePRC Principal Place of Business in Hong Kong 97943 43/F, One Taikoo Place, 979 King’s Road, Quarry Bay, Hong Kong www.interlong.com Websitewww.interlong.com 8329 Stock Code8329 Chairman’s Statement主席報告 Dear Shareholders, On behalf of the Board of Directors (the “Board”) of the Company, I ampleased to present the annual results of the Company and its subsidiaries(collectively the “Group”) for the year ended 31 December 2024 (the“Year”). In 2024, the pharmaceutical industry as a whole showed a steady recoveryand innovative development trend. The overall economic indicators of thepharmaceutical industry were robust, and the sub-sector of medical devicemaintained growth in revenue and profit. However, the sub-sectors ofchemical preparations and Chinese medicines, in which the Group is involved,recorded negative growth in operating revenue and profit. The centralizedprocurement of drugs continued to expand in terms of geographical andproduct variety coverage, exerting significant pressure on the profits of thesub-sectors of chemical preparations and Chinese medicines. Moreover, thenormalized and dynamic adjustment of the medical insurance catalog, as wellas the inclusion of more innovative drugs and generic drugs, has resulted inincreasingly fierce market competition. In response to the changing trends in pharmaceutical industry policiesand the current complex and volatile competitive environment, the Groupcontinued to make minor adjustments and refinements to its developmentstrategies. Firstly, the Group leveraged the collaboration advantage of theindustry structure and business structure of the Neptunus Headquarters, andutilized complementary resourc